(PDF) 460. Lentiviral-Mediated ENaCα Knockdown, as a

460. Lentiviral-Mediated ENaCα Knockdown, as a Treatment for Cystic Fibrosis Lung Disease

Molecular Therapy - United States

doi 10.1016/s1525-0016(16)34795-5

Full Text

Abstract

Available in full text

Categories

Molecular Medicine

Molecular Biology

Date

May 1, 2013

Authors

Unknown

Publisher

Elsevier BV

Related search

Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease

English

Outcome Measures for Clinical Trials Assessing Treatment of Cystic Fibrosis Lung Disease

Clinical Investigation

English

Origins of Cystic Fibrosis Lung Disease

New England Journal of Medicine

English

Challenges Facing microRNA Therapeutics for Cystic Fibrosis Lung Disease

Cancer Research

English

CXCR1andCXCR2haplotypes Synergistically Modulate Cystic Fibrosis Lung Disease

European Respiratory Journal

Respiratory Medicine

English

Genetic Influences on Cystic Fibrosis Lung Disease Severity

Frontiers in Pharmacology

English

Elucidating Progression of Early Cystic Fibrosis Lung Disease

European Respiratory Journal

Respiratory Medicine

English

Cell Therapy for Cystic Fibrosis Lung Disease: Regenerative Basal Cell Amplification

Stem cells translational medicine

Developmental Biology

English

Risk Factors for Lung Disease Progression in Children With Cystic Fibrosis

European Respiratory Journal

Respiratory Medicine

English